Bristol Myers gets regulatory clearance to close Mirati deal as FTC increases pressure on pharma M&A
Bristol Myers Squibb has the go-ahead from antitrust regulators to complete its $4.8 billion takeover of Mirati.
Increased FTC scrutiny has put large pharma mergers …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
